Johns Hopkins ABX Guide
Fexinidazole
INDICATIONS
FDA
FDA
- First-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to T. brucei gambiensein patients 6 years of age and older who weigh at least 20 kg.
- Due to decreased efficacy observed in patients with severe second-stage HAT, fexinidazole should only be used in these patients if no other options are available.
- This drug was developed as part of the Drugs for Neglected Diseases initiative.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 19, 2022
Citation
Dzintars, Kathryn . "Fexinidazole." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540775/5.2/Fexinidazole.
Dzintars K. Fexinidazole. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540775/5.2/Fexinidazole. Accessed December 26, 2024.
Dzintars, K. (2022). Fexinidazole. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540775/5.2/Fexinidazole
Dzintars K. Fexinidazole [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2024 December 26]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540775/5.2/Fexinidazole.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Fexinidazole
ID - 540775
A1 - Dzintars,Kathryn ,Pharm.D., BCPS
Y1 - 2022/10/19/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540775/5.2/Fexinidazole
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
